Logo image of VX1.DE

VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis

FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR

450.1  -1.9 (-0.42%)

Fundamental Rating

6

Taking everything into account, VX1 scores 6 out of 10 in our fundamental rating. VX1 was compared to 72 industry peers in the Biotechnology industry. VX1 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VX1 has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year VX1 was profitable.
In the past year VX1 has reported a negative cash flow from operations.
VX1 had positive earnings in 4 of the past 5 years.
Of the past 5 years VX1 4 years had a positive operating cash flow.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

VX1 has a better Return On Assets (-2.38%) than 69.44% of its industry peers.
VX1 has a Return On Equity of -3.26%. This is in the better half of the industry: VX1 outperforms 70.83% of its industry peers.
VX1 has a better Return On Invested Capital (16.31%) than 97.22% of its industry peers.
VX1 had an Average Return On Invested Capital over the past 3 years of 17.35%. This is significantly above the industry average of 11.80%.
Industry RankSector Rank
ROA -2.38%
ROE -3.26%
ROIC 16.31%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

With an excellent Operating Margin value of 39.89%, VX1 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of VX1 has grown nicely.
With an excellent Gross Margin value of 86.11%, VX1 belongs to the best of the industry, outperforming 81.94% of the companies in the same industry.
VX1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 39.89%
PM (TTM) N/A
GM 86.11%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VX1 is creating value.
Compared to 1 year ago, VX1 has less shares outstanding
Compared to 5 years ago, VX1 has less shares outstanding
Compared to 1 year ago, VX1 has an improved debt to assets ratio.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

VX1 has an Altman-Z score of 14.35. This indicates that VX1 is financially healthy and has little risk of bankruptcy at the moment.
VX1 has a better Altman-Z score (14.35) than 95.83% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that VX1 is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, VX1 belongs to the top of the industry, outperforming 84.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 14.35
ROIC/WACC1.77
WACC9.21%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 2.69 indicates that VX1 has no problem at all paying its short term obligations.
VX1 has a Current ratio (2.69) which is in line with its industry peers.
VX1 has a Quick Ratio of 2.35. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a Quick ratio of 2.35. This is comparable to the rest of the industry: VX1 outperforms 56.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.35
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for VX1 have decreased strongly by -98.09% in the last year.
VX1 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.14% yearly.
The Revenue has grown by 11.66% in the past year. This is quite good.
The Revenue has been growing by 21.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-98.09%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-5.24%
Revenue 1Y (TTM)11.66%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%15.66%

3.2 Future

Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 151.00% on average per year.
VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.03% yearly.
EPS Next Y6237.42%
EPS Next 2Y739.5%
EPS Next 3Y329.95%
EPS Next 5Y151%
Revenue Next Year9.78%
Revenue Next 2Y9.39%
Revenue Next 3Y9.24%
Revenue Next 5Y9.03%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30 40

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 1667.04, which means the current valuation is very expensive for VX1.
75.00% of the companies in the same industry are more expensive than VX1, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 29.35, VX1 is valued quite expensively.
Based on the Price/Forward Earnings ratio of 26.59, the valuation of VX1 can be described as expensive.
Based on the Price/Forward Earnings ratio, VX1 is valued cheaply inside the industry as 81.94% of the companies are valued more expensively.
VX1's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.10.
Industry RankSector Rank
PE 1667.04
Fwd PE 26.59
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 500 1K 1.5K

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VX1 indicates a somewhat cheap valuation: VX1 is cheaper than 77.78% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 25.29
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of VX1 may justify a higher PE ratio.
A more expensive valuation may be justified as VX1's earnings are expected to grow with 329.94% in the coming years.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y739.5%
EPS Next 3Y329.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VX1!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERTEX PHARMACEUTICALS INC

FRA:VX1 (3/7/2025, 7:00:00 PM)

450.1

-1.9 (-0.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2025-02-10/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners96.16%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap115.58B
Analysts76.92
Price Target489.06 (8.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.31%
Min EPS beat(2)-3.07%
Max EPS beat(2)3.69%
EPS beat(4)2
Avg EPS beat(4)-128.02%
Min EPS beat(4)-527.57%
Max EPS beat(4)14.85%
EPS beat(8)4
Avg EPS beat(8)-64.13%
EPS beat(12)7
Avg EPS beat(12)-41.66%
EPS beat(16)11
Avg EPS beat(16)-28.52%
Revenue beat(2)1
Avg Revenue beat(2)1.23%
Min Revenue beat(2)-0.22%
Max Revenue beat(2)2.68%
Revenue beat(4)2
Avg Revenue beat(4)0.55%
Min Revenue beat(4)-2.56%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.2%
Revenue beat(12)5
Avg Revenue beat(12)-0.06%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)2.53%
PT rev (3m)-2.62%
EPS NQ rev (1m)-2.54%
EPS NQ rev (3m)-2.97%
EPS NY rev (1m)-3.34%
EPS NY rev (3m)-3.96%
Revenue NQ rev (1m)1.82%
Revenue NQ rev (3m)2.07%
Revenue NY rev (1m)0.94%
Revenue NY rev (3m)1.16%
Valuation
Industry RankSector Rank
PE 1667.04
Fwd PE 26.59
P/S 11.39
P/FCF N/A
P/OCF N/A
P/B 7.65
P/tB 8.66
EV/EBITDA 25.29
EPS(TTM)0.27
EY0.06%
EPS(NY)16.93
Fwd EY3.76%
FCF(TTM)-3.51
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS39.53
BVpS58.86
TBVpS51.99
PEG (NY)0.27
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.38%
ROE -3.26%
ROCE 23.17%
ROIC 16.31%
ROICexc 27.37%
ROICexgc 32.95%
OM 39.89%
PM (TTM) N/A
GM 86.11%
FCFM N/A
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
ROICexc(3y)45.4%
ROICexc(5y)50.15%
ROICexgc(3y)65.51%
ROICexgc(5y)78.06%
ROCE(3y)24.64%
ROCE(5y)25.5%
ROICexcg growth 3Y-26.3%
ROICexcg growth 5Y-6.95%
ROICexc growth 3Y-19.26%
ROICexc growth 5Y0.61%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.02
Cap/Depr 234.27%
Cap/Sales 4.4%
Interest Coverage 144.12
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 2.35
Altman-Z 14.35
F-Score4
WACC9.21%
ROIC/WACC1.77
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.84%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-98.09%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-5.24%
EPS Next Y6237.42%
EPS Next 2Y739.5%
EPS Next 3Y329.95%
EPS Next 5Y151%
Revenue 1Y (TTM)11.66%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%15.66%
Revenue Next Year9.78%
Revenue Next 2Y9.39%
Revenue Next 3Y9.24%
Revenue Next 5Y9.03%
EBIT growth 1Y14.17%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year867.56%
EBIT Next 3Y128.8%
EBIT Next 5Y71.26%
FCF growth 1Y-129.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-113.93%
OCF growth 3YN/A
OCF growth 5YN/A